ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
•20 Jan 2025 10:56

GAPack (468 HK): IFA Says "Reject". But Mengniu Selling Down

The first close of XJF's Offer for Greatview Aseptic Packaging (468 HK) is the 21st January, and for a number of investors, the deadline to tender...

Logo
956 Views
Share
•20 Jan 2025 09:20

Millennium & Copthorne Hotels (MCK NZ): City Dev's Privatisation Offer

This is done. No other Offer will emerge. If small, illiquid arbs are your bent, look to enter here and on any weakness.

Logo
449 Views
Share
•20 Jan 2025 01:42

Merger Arb Mondays (20 Jan) - Canvest, Henlius, Lifestyle China, Vesync, JAMCO, Insignia, AVJennings

This week, the highest gross spreads are Henlius (29.3%), Smart Share (16.8%), Lifestyle China (16.7%), Seven & I (15.4%), Get Nice (13.3%), ESR...

Logo
472 Views
Share
bullish•WuXi AppTec
•19 Jan 2025 10:07

China Healthcare Weekly (Jan.19)- WuXi AppTec Sells Shares in WuXi XDC, National Biological Drug VBP

​Anhui to lead the national biological drug VBP, industry expected to rebound.EVER001 may be game changer for MN.Disposal of WuXi XDC shares may...

Logo
557 Views
Share
bullish•Insignia Financial
•19 Jan 2025 06:15

(Mostly) Asia-Pac M&A: Jamco, AVJennings, Insignia Financial, Advanced Info Service/Thaicom

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
469 Views
Share
x